| アブストラクト | Hepatosplenic T cell lymphoma (HSTCL) are rare cancers ( approximately 100 published cases worldwide) and comprise 5% of peripheral T cell lymphomas. As of October 5, 2006, the FDA's Adverse Event Reporting System has received 8 cases of HSTCL in young patients using infliximab, a tumor necrosis factor-alpha blocking agent, to treat inflammatory bowel disease (6 of the 8 cases had a fatal outcome). All 8 patients were receiving concomitant immunosuppressant therapy (eg, azathioprine, prednisone). It has not been established that infliximab had an exclusive or primary role in the pathogenesis of these HSTCL cases; however, it appears that patients using this product may be at greater risk for developing this rare lymphoma. |
|---|
| ジャーナル名 | Journal of pediatric gastroenterology and nutrition |
|---|
| 投稿日 | 2007/01/27 |
|---|
| 投稿者 | Mackey, Ann Corken; Green, Lanh; Liang, Li-Ching; Dinndorf, Patricia; Avigan, Mark |
|---|
| 組織名 | Center for Drug Evaluation and Research, US Food and Drug Administration,;Rockville, MD, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/17255842/ |
|---|
